Transient detection of β-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy

Experimental Hematology

Volumn 30, Issue 2, 2002, Pages 108-115

  Bagnis, Claude ^a   Chabannon, Christian ^a   Gravis, Gwenaelle ^a   Imbert, Anne Marie ^a   Maroc, Christine ^a   Bardin, Florence ^a   Ladaique, Patrick ^a   Viret, Frédéric ^a   Genre, Dominique ^a   Faucher, Catherine ^a   Stoppa, Anne Marie ^a   Vey, Norbert ^a   Blaise, Didier ^a   Maraninchi, Dominique ^a   Viens, Patrice ^a   Mannoni, Patrice ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MELPHALAN; MYELOABLATIVE AGENT; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; APHERESIS; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD CELL; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLONOGENESIS; COCULTURE; CONTROLLED STUDY; DNA MODIFICATION; ENZYME ACTIVITY; ESCHERICHIA COLI; FEASIBILITY STUDY; FEMALE; GENE TRANSFER; HEART FAILURE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INFUSION; MARKER GENE; MOLONEY LEUKEMIA ONCOVIRUS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SAFETY; STEM CELL; TACHYCARDIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-GALACTOSIDASE; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; MOLONEY MURINE LEUKEMIA VIRUS; OVARIAN NEOPLASMS; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MURINE LEUKEMIA VIRUS;

EID: 0036141476     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00773-1     Document Type: Article

References (49)

1. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
2. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
3. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
4. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
5. Engraftment of gene modified umbilical cord blood cells in neonates with adenosine deaminase deficiency
6. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy
7. + cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vitro
8. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures
9. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells
10. + cell populations and into TF-1 cells; future prospects in gene therapy
11. - fetal liver progenitors reconstitute the SCID-hu mouse and express the transgene in T, B, myeloerythroid and progenitor cells
12. + peripheral blood progenitors
13. Phase I study of a recombinant adenoviral-mediated gene transfer in lung cancer patients
14. Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells
15. + peripheral blood cells in patients with poor-prognosis breast cancer; a randomized multicenter study
16. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer; results of a prospective randomized multicenter clinical trial
17. A defective retroviral vector encoding human interferon-α 2 can transduce human leukemic cell lines
18. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow; implications for gene therapy
19. +-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice
20. + cord blood cells
21. + cells impairs their ability to differentiate towards the B-lymphoid lineage
22. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice
23. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells
24. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy
25. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism
26. The prokaryotic neomycin-resistance gene acts as a transcriptional silencer in eukaryotic cells
27. Cre/loxP-mediated excision of a neomycin resistance expression unit from an integrated retroviral vector increases long terminal repeat-driven transcription in human hematopoietic cells
28. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates
29. Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retrovirus vectors
30. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
31. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors; evidence of direct viral binding to chymotryptic carboxy-terminal fragments
32. Retroviral transduction of CD34-enriched hematopoietic progenitor cells under serum-free conditions
33. Efficiency of retroviral transduction into hematopoietic cells by cocultivation procedure does not correlate with viral titer
34. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
35. Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells
36. - human hematopoietic cells by HIV-1-based lentiviral vectors
37. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent
38. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells
39. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products
40. Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients
41. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-vs-leukemia
42. Herpes simplex virus thymidine kinase gene transfer for controlled graft-vs-host disease and graft-vs-leukemia; clinical follow-up and improved new vectors
43. Immune response to green fluorescent protein; implications for gene therapy
44. Abrogation of postmyeloablative chemotherapy neutropenia by ex vivo-expanded autologous CD34 cells
45. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo (retracted in NEJM, 2001, 345:64)
46. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma; a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry
47. + cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity
48. Megakaryocyte progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients